CHST15 and neoplasm: The authors administered an EUS-guided intratumoral injection of STNM01, a synthetic double-stranded RNA oligonucleotide against CHST15, resulting in significant suppression of tumoral CHST15 and a rapid induction of tumoral T-cell accumulation and prolongation of overall survival, which correlated significantly with the degree of increase in tumor-infiltrating CD3+ T cells at week 4 [98].